LV11615A - Amidi ar arstnieciskam ipasibam - Google Patents

Amidi ar arstnieciskam ipasibam

Info

Publication number
LV11615A
LV11615A LV960176A LV960176A LV11615A LV 11615 A LV11615 A LV 11615A LV 960176 A LV960176 A LV 960176A LV 960176 A LV960176 A LV 960176A LV 11615 A LV11615 A LV 11615A
Authority
LV
Latvia
Prior art keywords
amid
medical treatment
medical
treatment
Prior art date
Application number
LV960176A
Other languages
English (en)
Other versions
LV11615B (en
Inventor
George Chang
Peter H Dorf
George J Quallich
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002223574A external-priority patent/CA2223574C/en
Application filed by Pfizer filed Critical Pfizer
Publication of LV11615A publication Critical patent/LV11615A/lv
Publication of LV11615B publication Critical patent/LV11615B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LVP-96-176A 1995-06-07 1996-06-06 Therapeutic amides LV11615B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB1995/000448 WO1996040640A1 (en) 1995-06-07 1995-06-07 BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
CA002223574A CA2223574C (en) 1995-06-07 1995-06-07 Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and their use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein b (apo b) secretion
HU9601566A HUP9601566A3 (en) 1995-06-07 1996-06-06 Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component

Publications (2)

Publication Number Publication Date
LV11615A true LV11615A (lv) 1996-12-20
LV11615B LV11615B (en) 1997-04-20

Family

ID=89994037

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-96-176A LV11615B (en) 1995-06-07 1996-06-06 Therapeutic amides

Country Status (14)

Country Link
EP (1) EP0832069B1 (lv)
AP (1) AP9600804A0 (lv)
BR (1) BR9602628A (lv)
CZ (1) CZ289249B6 (lv)
FI (1) FI974440A (lv)
HR (1) HRP960270A2 (lv)
HU (1) HUP9601566A3 (lv)
IL (1) IL118484A (lv)
LV (1) LV11615B (lv)
NZ (1) NZ286733A (lv)
PL (1) PL314636A1 (lv)
SG (1) SG44952A1 (lv)
SI (1) SI9600183A (lv)
WO (1) WO1996040640A1 (lv)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
CN1209803A (zh) * 1996-01-16 1999-03-03 布里斯托尔-迈尔斯斯奎布公司 微粒体甘油三酯转移蛋白的构象限制性芳族抑制剂及方法
ATE223400T1 (de) * 1996-04-30 2002-09-15 Pfizer Verfahren und zwischenprodukte zur herstellung von 4-trifluoromethylbiphenyl-2-carbonsaüre,(2- (2h-(1,2,4) triazol-3-ylmethyl)-1,2,3,4- tetrahydro-isoquinolin-6-yl)-amide
US5885983A (en) * 1996-05-10 1999-03-23 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5827875A (en) * 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
TW438796B (en) * 1996-05-15 2001-06-07 Hoffmann La Roche 2,4-diaminopyrimidine derivatives, the manufacture process thereof, and the antibiotically-active pharmaceutical composition containing the same
US5883109A (en) * 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
KR100334567B1 (ko) * 1996-11-27 2002-05-03 디. 제이. 우드, 스피겔 알렌 제이 아포 비-분비/엠티피 억제성 아미드
US5760246A (en) * 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
PL336481A1 (en) * 1997-04-18 2000-06-19 Pfizer Method of obtaining (1,2,3,4- tetrahydroisoquinolin -6-yl) amide of 4'-trifluoromethylbiphenyl-2-carboxylic acid and intermediate compounds
GB9708119D0 (en) * 1997-04-22 1997-06-11 Glaxo Group Ltd Chemical compounds
US5968950A (en) * 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
AU4543899A (en) 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
CO5090829A1 (es) * 1998-07-21 2001-10-30 Novartis Ag Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b.
US6197798B1 (en) 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
GB9826412D0 (en) * 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
AU6824700A (en) * 1999-07-20 2001-02-05 Novartis Ag Organic compounds
CA2324801A1 (en) * 1999-11-10 2001-05-10 Andrew Gordon Swick Use of apo b secretion/mtp inhibitors and anti-obesity agents
CO5271688A1 (es) * 1999-11-10 2003-04-30 Pfizer Prod Inc Uso de inhibidor de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsmales
IL139450A0 (en) * 1999-11-10 2001-11-25 Pfizer Prod Inc Methods of administering apo b-secretion/mtp inhibitors
CA2324800A1 (en) * 1999-11-10 2001-05-10 Mary Anne Hickman Use of apo b secretion/mtp inhibitors
WO2001077077A1 (en) * 2000-04-10 2001-10-18 Novartis Ag Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
GB0013383D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
DE10033337A1 (de) * 2000-07-08 2002-01-17 Boehringer Ingelheim Pharma Biphenylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
WO2002014276A1 (fr) * 2000-08-10 2002-02-21 Tanabe Seiyaku Co., Ltd. Composes a base de benzoylaminoisoindoline, leurs procedes de preparation et produits intermediaires utilises dans leur synthese
AU2001277728A1 (en) * 2000-08-10 2002-02-25 Tanabe Seiyaku Co., Ltd. Biphenylcarboxamidoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
EP1326835A1 (en) * 2000-10-05 2003-07-16 Fujisawa Pharmaceutical Co., Ltd. Benzamide compounds as apo b secretion inhibitors
JO2409B1 (en) 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
JO2390B1 (en) * 2001-04-06 2007-06-17 شركة جانسين فارماسوتيكا ان. في Diphenylcarboxamides act as lipid-lowering agents
WO2002090347A1 (en) * 2001-04-30 2002-11-14 Fujisawa Pharmaceutical Co., Ltd. Amide compounds
EE05452B1 (et) * 2001-06-28 2011-08-15 Pfizer Products Inc. Triamiidasendatud indoolid, bensofuraanid ja bensotiofeenid kui mikrosomaalse trigltseriidide transportvalgu (MTP) ja/v?i apolipoproteiin B (apoB) sekretsiooni inhibiitorid
CA2468716A1 (en) * 2001-11-28 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic amide compounds as apolipoprotein b inhibitors
GB0129015D0 (en) * 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds
GB0129013D0 (en) * 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds
EP2033953A1 (en) * 2002-02-15 2009-03-11 Glaxo Group Limited Vanilloid receptor modulators
CN101838218A (zh) 2002-02-28 2010-09-22 日本烟草产业株式会社 酯化合物及其医药用途
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
PL1651232T3 (pl) * 2003-07-23 2011-05-31 Synta Pharmaceuticals Corp Związki do zastosowań związanych z zapaleniami i odpornością
JP4832897B2 (ja) 2003-08-29 2011-12-07 日本たばこ産業株式会社 エステル誘導体及びその医薬用途
JP2007525482A (ja) * 2003-10-07 2007-09-06 レノビス, インコーポレイテッド イオンチャネルリガンドとしてのアミド化合物およびその使用
GB2413129A (en) * 2003-10-07 2005-10-19 Renovis Inc Aromatic amide compounds as ion channel ligands and uses thereof
AU2005214159A1 (en) 2004-02-04 2005-09-01 Pfizer Products Inc. Substituted quinoline compounds
RS52825B2 (sr) 2004-03-05 2018-03-30 Univ Pennsylvania Postupci za lečenje poremećaja ili bolesti povezanih sa hiperlipidemijom i hiperholesterolemijom uz minimizaciju sporednih efekata
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
JP2006249022A (ja) 2005-03-11 2006-09-21 Sumitomo Chemical Co Ltd 4−(2−メチルフェニル)ベンゾトリフルオライドの製造方法
AU2006236226B2 (en) 2005-04-19 2012-07-05 Surface Logix, Inc. Inhibitors of microsomal triglyceride transfer protein and Apo-B secretion
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
DE102005062987A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
DK2046787T3 (da) 2006-08-01 2011-07-18 Glaxo Group Ltd Pyrazolo[3,4-B]pyridin-forbindelser, og deres anvendelse som PDE4-inhibitorer
JO2653B1 (en) * 2006-10-24 2012-06-17 شركة جانسين فارماسوتيكا ان. في Tetrahydroflavin 1-carboxylic acid substituted with pyridine or pyrazine inhibit MTB
ATE469122T1 (de) 2006-10-24 2010-06-15 Janssen Pharmaceutica Nv Mtp-inhibierende tetrahydronaphthalin-1- carbonsäurederivate
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
AU2014255381A1 (en) 2013-04-17 2015-10-08 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
MX2021008533A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022900A (en) * 1970-09-09 1977-05-10 Marion Laboratories, Inc. Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
CA1248536A (en) * 1982-09-10 1989-01-10 Wellcome Foundation Limited (The) Benzoil acid derivatives
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicycle compounds and pharmaceuticals containing them

Also Published As

Publication number Publication date
BR9602628A (pt) 1998-09-08
IL118484A (en) 2001-11-25
CZ289249B6 (cs) 2001-12-12
WO1996040640A1 (en) 1996-12-19
FI974440A0 (fi) 1997-12-05
PL314636A1 (en) 1996-12-09
SI9600183A (en) 1997-04-30
HUP9601566A3 (en) 1998-01-28
HRP960270A2 (en) 1997-12-31
EP0832069B1 (en) 2003-03-05
AP9600804A0 (en) 1997-11-09
FI974440A (fi) 1998-01-27
CZ164496A3 (en) 1997-01-15
EP0832069A1 (en) 1998-04-01
SG44952A1 (en) 1997-12-19
HUP9601566A2 (en) 1997-09-29
LV11615B (en) 1997-04-20
NZ286733A (en) 1998-02-26
IL118484A0 (en) 1996-09-12

Similar Documents

Publication Publication Date Title
LV11615A (lv) Amidi ar arstnieciskam ipasibam
DE69623722D1 (de) Blutbehandlungsgerät
NO953838D0 (no) Fjernbart medisinsk elektrodesystem
DK0747069T3 (da) Implanterbar medicinsk anordning
DE69606550D1 (de) Medizinischen verbindungsanordnung
DE69522448D1 (de) Gewebebehandlungskassette
NO976063D0 (no) Fremgangsmåte for behandling av diabetes
DE69630543D1 (de) Medizinische elektrodenleitung
DE69614680T2 (de) Implantierbare osteosynthesevorrichtung
DE69630305D1 (de) Elektrodenkatheter
FR2716363B1 (fr) Instrument de thérapie endoscopique.
TR199600481A2 (tr) Tedavi edici amidler.
DE19681419T1 (de) Behandlungssystem
GB2303303B (en) Medical treatment
GB9521725D0 (en) Medical treatment
DE69614890D1 (de) Hautstreckmaschine
DE59610423D1 (de) Partikulare arzneiform
DE59607418D1 (de) Haarbehandlungsmittel
GB9526264D0 (en) Medical treatment
DK48194A (da) Medicinsk elektrode
KR960030492U (ko) 의료용 멸균기
DK0734514T3 (da) Vævsprøvebehandling
KR970003938U (ko) 환자 보조용 헬멧
UA915S (uk) Канюля медична
KR960030471U (ko) 환자용 베드